Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

Acta Dermato-Venereologica

Volumn 90, Issue 2, 2010, Pages 183-185

  Brunasso, Alexandra M G ^a,b   Laimer, Martin ^c   Massone, Cesare ^b  

^a GALLIERA HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; CALCITRIOL; CORTICOSTEROID; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID;

ABDOMINAL PAIN; ADULT; ANEMIA; ANKLE PAIN; ARTHRALGIA; BIOLOGICAL THERAPY; BURNING SENSATION; CASE REPORT; DRUG ERUPTION; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LETTER; LEUKOPENIA; MALE; PAPULE; PHYTOTHERAPY; POLYSEROSITIS; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; PYODERMA GANGRENOSUM; RECTUM HEMORRHAGE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; PYODERMA GANGRENOSUM; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 77950276066     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0777     Document Type: Letter

References (15)

1. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis: a meta-analysis. Pharmacology 2008; 83: 1-9.
2. Silman A, Symmons D, Scott GI, Griffiths I. British Society for Rheumatology Biologies Register. Ann Rheum Dis 2003; 62: ii28-ii29.
3. Italian PsoCare National Registry. Available from: URL: http://www.psocare.it/cms/home-eng [accessed 2009 Jan 11].
4. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143: 223-231.
5. Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol 2007; 26: 2.
6. Strober BE, Siu K, Menon K. Convenional systemic agents for psoriasis. J Rheumatol 2006; 33: 1442-1446.
7. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886-890.
8. Okamoto H. Effect of rituximab in refractory SLE: inhibition of Th1? Rheumatology 2006; 45: 121-122.
9. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252.
10. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology 2007; 215: 245-251.
11. Vandevyvere K, Luyten FP, Verschueren P, Lories R, Segaert S, Westhovens R. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26: 2205-2206.
12. Brunasso AM, Massone C. Trombocytopenia related with anti-TNF-α agents for psoriasis. J Am Acad Dermatol 2009; 60: 781-785.
13. Warkentin TE, Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 2005; 143: 761-763.
14. Litton G. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept. Am J Hematol 2008; 83: 344.
15. Somers HM, Somers AR. The paradox of medical progress. N Engl J Med 1962; 266: 1253-1258.